Delving into the Latest Updates on CS-060380 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

THR-β

Mechanism

THR-β agonists(Thyroid hormone receptor beta-1 agonists)

Therapeutic Areas

Digestive System DisordersEndocrinology and Metabolic Disease

Active Indication

Hyper LDL cholesterolaemiaNonalcoholic Steatohepatitis

Inactive Indication-

Originator Organization

Case Kaidi (Shanghai) Pharmaceutical Technology Co., Ltd.

Active Organization

Case Kaidi (Shanghai) Pharmaceutical Technology Co., Ltd.

Kaisi Kaidi (Shanghai) Pharmaceutical Technology Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：考察健康和 LDL-C 升高受试者单次和多次口服 CS060380 的安全性和耐受性次要目的：考察健康和 LDL-C 升高受试者单次和多次口服 CS060380 的 PK特征，评价食物对健康受试者单次服用 CS060380 后 PK 特征的影响探索性目的：探索LDL-C升高受试者多次口服 CS060380 的效动力学（PD）特征、甲状腺功能的影响、对QT间期的影响

[Translation]

Primary purpose: To investigate the safety and tolerability of single and multiple oral administration of CS060380 in healthy and LDL-C elevated subjects Secondary purpose: To investigate the PK characteristics of single and multiple oral administration of CS060380 in healthy and LDL-C elevated subjects, and to evaluate the effect of food on the PK characteristics of CS060380 after a single dose in healthy subjects Exploratory purpose: To explore the PD characteristics, effect on thyroid function, and effect on QT interval of multiple oral administration of CS060380 in LDL-C elevated subjects

Start Date-

Sponsor / Collaborator

Case Kaidi (Shanghai) Pharmaceutical Technology Co., Ltd.

NCT06573528 / Not yet recruitingPhase 1

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Food Effect of Randomized, Double-Blind, Placebo-Controlled Single and Multiple Dose Escalations of CS060380 in Healthy and Elevated LDL-C Subjects

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060380 in Healthy and Elevated LDL-C Subjects.

Start Date30 Aug 2024

Sponsor / Collaborator

Kaisi Kaidi (Shanghai) Pharmaceutical Technology Co., Ltd.

100 Clinical Results associated with CS-060380

Login to view more data

100 Translational Medicine associated with CS-060380

Login to view more data

100 Patents (Medical) associated with CS-060380

Login to view more data

100 Deals associated with CS-060380

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hyper LDL cholesterolaemia	Phase 1	CN	Kaisi Kaidi (Shanghai) Pharmaceutical Technology Co., Ltd.	30 Aug 2024
Nonalcoholic Steatohepatitis	Phase 1	CN	Case Kaidi (Shanghai) Pharmaceutical Technology Co., Ltd.	20 Aug 2024